Meridian Bioscience‘s (NASDAQ:VIVO) has two molecular diagnostic tests in clinical trials, with another test expected to begin trials later in the year. Currently in trials are tests built on the company’s illumigene molecular diagnostic testing platform for Mycoplasma pneumonia, an infection of the lungs, and group A streptococcus, a type of bacteria often found in […]
Meridian Bioscience (NASDAQ:VIVO) has reached a deal to offer discounted prices for two molecular diagnostics tests to members of one of the nation’s largest healthcare group purchasing organizations. Cincinnati-area Meridian hopes the deal with Premier, a hospital-owned quality improvement alliance that boasts more than 2,500 hospital members, adds a spark to sales of two molecular […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received Australian regulatory clearance of a molecular test for group B streptococcus. The test is part of Cincinnati-area Meridian’s illumigene line of molecular diagnostic tests. The illumigene product line is key to Meridian’s future as more customers look to molecular diagnostics, a means of analyzing the makeup of […]
Diagnostics company Meridian Bioscience (NASDAQ:VIVO) has received U.S. Food and Drug Administration clearance for a test to detect bacteria commonly associated with Legionnaires’ disease. Legionnaires’ disease is a severe lung inflammation caused by an infection. Cincinnati, Ohio-area Meridian said the test, called TRU Legionella, is an important addition to its respiratory product portfolio. “This new […]
Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is currently in clinical trials, according to a statement from Meridian announcing the Cincinnati-area company’s first-quarter earnings. Meridian plans to launch three to four new illumigene tests per […]
Diagnostic test maker Meridian Bioscience‘s (NYSE:VIVO) Chief Executive Jack Kraeutler received a 3 percent increase in compensation this year to $843,000. Here’s how Kraeutler’s 2011 compensation breaks down, according to a recent regulatory filing: $546,000 in base salary; $228,000 in stock awards and $69,000 in “other” compensation, which includes retirement contributions, auto allowance and financial […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus. The group B strep test is the second in the Cincinnati-area company’s illumigene line of molecular diagnostic tests to be cleared by the U.S. Food and Drug Administration. The illumigene product line is key to Meridian’s […]
Diagnostic testing company Meridian Bioscience (NASDAQ:VIVO) has filed a regulatory document that gives it the right to sell additional common and preferred shares. The document didn’t specify a dollar amount or number of shares the company could sell, or a date by which the company would make the sale. However, the document notes that Meridian […]
Meridian Bioscience (NASDAQ:VIVO) plans to launch up to four new tests from its illumigene molecular diagnostic testing platform over the next year. Cincinnati-area Meridian is betting big on the illumigene platform, which it says provides its hospital and laboratory customers with a simpler, cheaper option to test samples for certain types of bacteria without the […]
Market adoption of Meridian Bioscience’s (NASDAQ:VIVO) new molecular diagnostic testing platform illumigene will go a long way toward determining the company’s future. Cincinnati-area Meridian is betting big on the technology, hoping it’ll help rescue the diagnostic testing company from its recent struggles. The company has reported declining year-over-year earnings in several recent quarters and twice […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
More bad news for investors in diagnostic testing company Meridian Bioscience (NASDAQ:VIVO). The Cincinnati-area company now projects its full-year results to come in at the “lower end” of a range of 68 cents to 71 cents per share, according to a statement. The news comes after Meridian last month pushed its guidance down from its […]
Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In recent years, C. difficile infections have become more frequent, more severe and more difficult to treat, according to Mayo Clinic. This […]
Diagnostic testing company Meridian Bioscience (Nasdaq: VIVO) saw its shares fall as much as 13 percent in early trading Thursday, as the company downwardly revised its full-year earnings outlook. Shares of Meridian, whose tests can help doctors detect c. diff infection symptoms, were hovering around $23.87 in late-morning trading, after closing at $27.32 the prior […]
Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received U.S. Food and Drug Administration clearance for a new C. difficile test. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In recent years, C. difficile infections have become more frequent, more severe and more difficult to treat, […]
MedCity News’ Brandon Glenn breaks down the recent FDA approval of Meridian Bioscience’s pediatric version of its C. difficile test on this week’s edition of Health Journal on ONN. Meridian said its new product is the only C. difficile test that the U.S. Food and Drug Administration has cleared for use on children under the […]